Medical/Pharmaceuticals

Complete Genomics and Gencove Announce agreement at Plant and Animal Genome Conference (PAG 31) to offer a bundled solution for low-pass whole genome sequencing

SAN JOSE, Calif., Jan. 16, 2024 /PRNewswire/ -- Complete Genomics , a life sciences company that provides novel, end-to-end DNA sequencing solutions, today announced a joint marketing agreement withGencove,  a pioneer of low-pass whole gen...

2024-01-16 22:00 2662

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors

CHENGDU, China, Jan. 16, 2024 /PRNewswire/ -- Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewWay) announced that onJanuary 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody (bsAb), NWY001, at Sun Yat-Sen University Cancer Center inChina,...

2024-01-16 17:00 2869

PranaQ to Unveil Revolutionary Sleep Tech at CES 2024: Introducing TipTraQ, the AI Sleep Tracking and Improvement Solution

NEW YORK, Jan. 15, 2024 /PRNewswire/ -- PranaQ, the innovative sleep tech startup, has made waves at CES 2024 with the highly anticipated launch of its flagship product, TipTraQ. This cutting-edge device goes beyond traditional sleep monitoring, offering a comprehensive solution for diagnosing an...

2024-01-16 00:00 2618

CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection

SHANGHAI, Jan. 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that CT011, an autologous CAR T-cell product candidate against Glypic...

2024-01-15 21:50 3063

Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia

SHANGHAI, Jan. 14, 2024 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical-stage innovative biopharmaceutical company, announced recently that the company has completed a Phase Ib study, "An Open-Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgene...

2024-01-15 08:08 3853

San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry

SAN FRANCISCO, Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus toSan Francisco. The J.P. Morgan Healthcare Conference has been successfully held here for 42 editions, becoming a hall where industry thought converges and spar...

2024-01-12 23:28 7433

Qilian International Holding Group Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule

JIUQUAN, China, Jan. 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI ) ("Qilian" or the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that onJanuary 10, 2024,...

2024-01-12 20:30 6411

ClinChoice Acquires CSI, Expanding its Global Footprint into Southeast Asia

SHANGHAI, PHILADELPHIA and SINGAPORE, Jan. 11, 2024 /PRNewswire/ -- ClinChoice, a leading global Contract Research Organization (CRO), today announced expanding its global footprint with the acquisition of CSI Medical Research (CSI). CSI is a regional clinical CRO with professional staff and part...

2024-01-12 11:00 4378

United Imaging Intelligence Highlights Dedications to Advancing Intelligent Healthcare at RSNA Conference 2023

BOSTON, Jan. 11, 2024 /PRNewswire/ -- The Radiological Society of North America (RSNA) has concluded its annual meeting inChicago, IL, serving as a platform for revolutionary advancements in the field of radiology. United Imaging Intelligence (UII), an innovative subsidiary of United Imaging Grou...

2024-01-11 22:00 3144

GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia

SHANGHAI, Jan. 11, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology, announced that U.S. Food and Drug Administration (FDA) has recently granted another two designations for SLS009 (GFH009). GFH009 (hig...

2024-01-11 19:00 2528

CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference

SAN FRANCISCO, Jan. 11, 2024 /PRNewswire/ -- The 42nd J.P. Morgan Annual Healthcare Conference("JPMHC")2024 is taking place onJanuary 8-11 at San Fracisco,USA, members of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, Kelun-Biotech) senior management team participated in the conferen...

2024-01-11 17:55 2743

SyntheticGestalt and Enamine to Collaborate on the Creation of AI-Based Model to Facilitate Drug Discovery

SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates. This model will utilize 38 billion compounds from Enamine REAL database as a dataset for pre-training. TOKYO and KYIV, Ukraine, Jan. 11, 2024 /PRNewswire/ -- SyntheticGestalt, a research and ...

2024-01-11 16:00 2369

Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a commercial stage global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that Dr.Dajun Yang, the company's ...

2024-01-11 11:53 5561

Robooter Showcases Innovative Power Wheelchair X40 at CES 2024

LAS VEGAS, Jan. 10, 2024 /PRNewswire/ -- Robooter, a leading autonomous mobility device manufacturer renowned for its robotic technology supporting the elderly and disabled, is proud to present the innovative power wheelchair X40 and offer a new space and mobility solution through its partners at...

2024-01-11 01:00 2402

New Chinese medicine drug developed by HKBU for myofibrillar myopathy granted orphan drug designation by FDA

HONG KONG, Jan. 10, 2024 /PRNewswire/ -- The Centre for Chinese Herbal Medicine Drug Development  of Hong Kong Baptist University (HKBU) has developed a new drug using effective components of a Chinese herbal medicine, Chaenomelis Fructus, for the treatment of the rare...

2024-01-10 16:50 2816

LOTTE BIOLOGICS Announces Songdo Bio Plant Development Plan at JPM Healthcare Conference 2024

* Richard Lee, CEO of LOTTE BIOLOGICS, delivers a keynote speech at the JPM Healthcare Conference for the second consecutive year * Unveils company's bio plant development plan in Songdo to meet clients' needs SEOUL, South Korea, Jan. 9, 2024 /PRNewswire/ -- LOTTE BIOLOGICS (CEO Richard Lee) ...

2024-01-10 08:55 4347

Toratani Co., Ltd. Unveils Groundbreaking "Virtuous Circulation Pillow and Mattress" with Patented Technology for Enhanced Deep Breathing Experience

New sleeping solutions that facilitate deeper breathing, improve sleep quality, and bring health benefits TOKYO, Jan. 9, 2024 /PRNewswire/ -- Toratani Co., Ltd. (Kahoku City, Ishikawa Prefecture,Japan) has announced the launch of their innovative Toratani Virtuous Circulation Mattress and Pillow...

2024-01-09 21:00 1905

Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion

SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock code :688176.SH) has announced its set-up of the Women's Health Business Unit for commercialization. This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women'...

2024-01-09 12:25 2542

Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib (ABSK021)

SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib(ABSK021) has been granted orphan drug designation(ODD) by the European Medicines Agency (EMA) for the treatm...

2024-01-09 08:30 2481

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site

Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, b...

2024-01-08 22:00 6336
1 ... 144145146147148149150 ... 262